Lynavoy: Breakthrough in Treating PBC Pruritus

Created using ChatSlide

Explore the intricacies of Primary Biliary Cholangitis (PBC) with a focus on its symptoms, prevalence, and the impact of cholestatic pruritus. Review established treatment guidelines, highlighting the primary therapies for PBC and pruritus, and underscoring the need for FDA-approved options. Delve into Lynavoy (Linerixibat), an IBAT inhibitor, detailing its approval, administration, dosing, and GLISTEN trial outcomes. Evaluate its efficacy, safety, and monitoring necessities. Finally,...